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Autophagy is an essential cellular process that removes harmful protein species, and 27 
autophagy upregulation may be able to protect against neurodegeneration and 28 
various pathogens. Here, we have identified the essential protein VCP/p97 as a 29 
novel regulator of autophagosome biogenesis, where VCP regulates autophagy 30 
induction in two ways, both dependent on Beclin-1. Utilizing small-molecule inhibitors 31 
of VCP ATPase activity, we show that VCP stabilizes Beclin-1 levels by promoting 32 
the deubiquitinase activity of Ataxin-3 towards Beclin-1. VCP also regulates the 33 
assembly and activity of the Beclin-1-containing phosphatidylinositol-3-kinase (PI3K) 34 
complex I, thus regulating the production of PI(3)P, a key signaling lipid responsible 35 
for the recruitment of downstream autophagy factors. Decreased levels of VCP, or 36 
inhibition of its ATPase activity impairs starvation-induced production of PI(3)P and 37 
 
 2 
limits downstream recruitment of WIPI2, ATG16L and LC3, thereby decreasing 38 
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 45 
Introduction 46 
Macroautophagy (henceforth autophagy) is an essential cellular process for 47 
degradation and recycling of cytosolic material, including entire organelles. These 48 
substrates are engulfed by double-membrane cup-shaped structures called 49 
phagophores. After the edges of the phagophores close, they become known as 50 
autophagosomes, which ultimately fuse to lysosomes to enable their degradation. 51 
Autophagy protects against the accumulation of damaged and dysfunctional 52 
components. The ability to upregulate autophagy is desirable from a therapeutic 53 
perspective as it protects against several metabolic and neurodegenerative diseases, 54 
as well as against cancer initiation 1. 55 
 56 
During autophagy induction, the sites of phagophore formation are determined by a 57 
confined enrichment of the lipid phosphatidyinositol-3-phosphate (PI(3)P) on 58 
precursor membranes 2-4. The PI(3)P is produced by the phosphatidyinositol-3-kinase 59 
(PI3K) complex I, consisting of the kinase VPS34 together with the regulatory 60 
proteins VPS15, Beclin-1 and ATG14L. Many upstream signaling pathways converge 61 
to regulate this kinase complex and the levels of its components in order to modulate 62 
autophagy 5. PI3K kinase activity results in the recruitment of PI(3)P-binding proteins, 63 
which eventually mediate the conjugation of ATG8 family proteins, such as LC3, to 64 
phosphatidylethanolamine in phagophore membranes 6,7. Lipid-conjugated LC3 65 
levels (LC3-II) correlate with autophagic load and LC3-II levels in the presence of 66 
lysosomal inhibitors (like Bafilomycin A1) reflect rates of LC3-II/autophagosome 67 
formation 8.  68 
 69 
Here we have identified Valosin-containing protein (VCP, also called p97), an 70 
essential and evolutionary conserved ATPase associated with diverse cellular 71 
activities 9, as a novel regulator of autophagy initiation. Our findings are distinct from 72 
previous studies that have observed that cells expressing dysfunctional versions of 73 
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VCP accumulate immature autophagic vesicles, positive for LC3 and p62 10-12, and 74 
display defects in autophagic clearance 13-16, indicative of a role in autophagosome 75 
maturation and fusion with the lysosome.  76 
 77 
The role of VCP in autophagosome maturation has been attributed to VCP affecting 78 
multiple steps of endocytosis. This may affect autophagic flux, as autophagosome-79 
endosome fusion precedes autophagosome-lysosome fusion 17. VCP interacts with 80 
the endocytic coat protein Clathrin, and regulate caveolin trafficking through the 81 
endosomal system 15,18. Furthermore, VCP has been suggested to regulate the 82 
oligomeric assembly of EEA1 oligomers, thereby governing the size and trafficking 83 
rate of early endosomes 14. In addition, VCP has been implicated in the autophagic 84 
removal of lysosomes themselves (lysophagy) 13, by modulating ubiquitin linkages on 85 
damaged lysosomes to enable LC3 binding and recruitment to autophagosomes. 86 
Thus, the mechanisms for VCP regulation of autophagosome maturation involves 87 
both endosomal transport as well as maintenance of a healthy pool of lysosomes. 88 
 89 
Here, we exploit the ability to acutely inhibit VCP activity with small-molecule 90 
inhibitors to show that VCP regulates autophagy induction and the formation of 91 
autophagosomes, in addition to regulating autophagosome maturation. We identify 92 
VCP as a novel interactor of the key autophagy protein Beclin-1 and show that VCP 93 
stimulates Ataxin-3-dependent stabilization of Beclin-1 levels. In addition, VCP acts 94 
to enhance the assembly and activity of the Beclin-1-containing PI3K complex in a 95 
manner independent of Ataxin-3. Through these two mechanisms, VCP stimulates 96 
the production of PI(3)P, and governs the recruitment of early autophagosome 97 
markers, thereby fulfilling an important role in early initiation of autophagy. 98 
 99 




VCP interacts with Beclin-1 and affects autophagy  102 
PI(3)P formation in autophagy initiation is Beclin-1-dependent, and we have 103 
previously shown that Ataxin-3 interacts with Beclin-1 and regulates the levels of this 104 
protein, thereby influencing autophagy19. Other studies have showed that Ataxin-3 105 
interacts with the major ATPase VCP 20-23, and we thus hypothesized that VCP could 106 
interact with Beclin-1, directly or indirectly, and possibly play a role in Beclin-1 107 
dependent autophagy. We could indeed verify the endogenous interaction of these 108 
two proteins in human cells (Fig. 1a), where VCP co-immunoprecipitated with Beclin-109 
1. To gain mechanistic insights into the interaction between VCP and Beclin-1 we 110 
attempted to map the binding site using truncated versions of Beclin-1 24. While we 111 
were able to confirm the interaction between VCP and full-length Beclin-1 in vitro, we 112 
could not pinpoint a specific region of Beclin-1 responsible for VCP binding, as VCP 113 
was found to bind all of the different truncated proteins of Beclin-1 (Extended Data 114 
Fig. 1a-c). While this could indicate that VCP is able to interact with Beclin-1 at 115 
several sites, this could also be a consequence of improper folding of the Beclin-1 116 
truncations leading to recognition by the chaperone-like activity of VCP 25. 117 
 118 
The interaction between the two proteins both in vivo and in vitro prompted us to test 119 
if VCP regulated Beclin-1-dependent autophagosome biogenesis. This would 120 
represent a new role for VCP in autophagy initiation, in addition to its reported 121 
functions in autophagosome maturation/clearance 10-12. In order to distinguish 122 
between effects on autophagosome formation and degradation, we acutely inhibited 123 
VCP activity with the reversible inhibitor DBeQ and combined this with pre-treatment 124 
using Bafilomycin A1 (BafA) to impair lysosome activity, which allowed us to assess 125 
LC3-II/autophagosome formation. In both basal and starvation conditions (where 126 
autophagy is induced), DBeQ caused an accumulation of LC3-II in the absence of 127 
BafA, but a decrease in LC3-II levels in the presence of BafA, corresponding to a 128 
combined phenotype where both autophagosome formation and degradation are 129 
impaired (Fig. 1b-c). The impaired starvation response upon VCP inhibition with 130 
DBeQ could be recapitulated in mouse primary cortical neurons (Extended Data Fig. 131 
1d), and was further demonstrated by the absence of starvation-induced LC3 puncta 132 
in cells (Fig. 1d-e). Inhibition of the starvation response was further recapitulated 133 
using additional commercial VCP inhibitors, where both the allosteric inhibitor 134 
NMS873 26, and the competitive DBeQ analogue CB-5083 27 impaired the increase of 135 




The loss of LC3 induction upon VCP inhibition was accompanied with a reduction in 138 
the production of PI(3)P by the Beclin-1-containing PI3K complex, which is an early 139 
signal for autophagy induction that acts upstream of LC3 recruitment to 140 
autophagosomes 5. We found that starvation-induced PI(3)P production was 141 
impaired upon acute VCP inhibition with DBeQ (Fig. 1f and Extended data figure 2d) 142 
as well as with the VCP inhibitors NMS873 and CB-5083 (Extended Data Fig. 2e-g). 143 
The extent of reduction in starvation-induced PI3K activity for VCP inhibition was in 144 
the same range as following direct PI3K kinase inhibition by Wortmannin or IN1 145 
(Fig.1f and Extended Data Fig.  2d-g), indicating a strong dependence of VCP 146 
activity for PI(3)P production. Additionally, VCP knockdown impaired ATG5-12 147 
conjugation, an early step preceding LC3-II formation which is Beclin-1/PI(3)P-148 
dependent 28, further supporting a role for VCP in autophagy initiation (Extended data 149 
Fig. 2h).  150 
 151 
While loss of PI(3)P induction upon starvation could be seen also upon siRNA-152 
mediated knockdown of VCP (Extended Data Fig. 3a-b), the defect in LC3-II 153 
(autophagosome formation) production seen with VCP inhibitors could not be 154 
replicated using this genetic knockdown approach (Extended Data Fig 3c-d), possibly 155 
due to the long-term accumulation of autophagosomes masking any visible effects 156 
on formation enabled by 4 h BafA treatment at the end of the experiment, or 157 
secondary effects arising during the prolonged depletion of an essential protein. 158 
Indeed, we observed that knockdown of VCP even using low concentrations of 159 
siRNA resulted in growth arrest and a large proportion of cell death (not shown), in 160 
agreement with previously published studies 29,30. Thus, the acute inhibition of VCP 161 
using available inhibitors provides us with a tool for studying its role in essential 162 
cellular processes, while avoiding the detrimental effects of VCP knockdown. 163 
 164 
VCP governs the recruitment of early autophagy markers  165 
To further focus on the effects on VCP on early autophagy initiation, we studied the 166 
appearance of early autophagy markers, which, unlike LC3 levels, would be 167 
unaffected by a potential block in autophagosome fusion to the lysosome, thus 168 
allowing us to discriminate between the role of VCP in autophagy induction versus its 169 
role in autophagosome maturation. WD repeat domain phosphoinositide-interacting 170 
protein 2 (WIPI2) is recruited to sites of autophagy initiation by binding to PI(3)P and, 171 
in turn, recruits the ATG12-ATG5-ATG16L complex to enable downstream 172 
recruitment and conjugation of LC3 to the forming autophagosome membranes 31. 173 
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We found that inhibition of VCP with DBeQ significantly impaired starvation-induced 174 
accumulation of both WIPI2 (Fig. 2a-b) and ATG16L puncta (Fig 2c-d), as would be 175 
expected after the decreased production of PI(3)P. The same effect was seen using 176 
additional VCP inhibitors NMS873 and CB-5083 (Extended Data Fig. 4a-b and 4d-e). 177 
In addition to the observed impairment of starvation-induced autophagy, we also 178 
found LC3 puncta accumulation upon treatment with the mTOR inhibitor, Torin 1 179 
(which recapitulates the mTORC1 inhibition component of starvation-induced 180 
autophagy), to be abolished by VCP inhibition (Extended Data Fig 4c and 4f). Thus, 181 
VCP interacts with Beclin-1 and is important for PI(3)P production by the Beclin-1-182 
containing PI3K complex during multiple scenarios of autophagy induction. 183 
 184 
VCP stabilizes Beclin-1 levels via Ataxin-3  185 
Genetic knockdown of VCP expression or inhibition of VCP activity reduced Beclin-1 186 
protein levels in both primary mouse neurons and in human cells (Fig. 3a, and 187 
Extended Data Fig. 5a-b). VCP inhibition with DBeQ also reduced Beclin-1 levels in 188 
the presence of the translational inhibitor cycloheximide (CHX), which was blocked 189 
by the addition of the proteasome inhibitor MG132, suggesting that VCP inhibition 190 
caused more rapid proteasomal degradation of Beclin-1 (Fig. 3b). Thus, loss of VCP 191 
function leads to destabilization of Beclin-1 and a decreased production of PI(3)P 192 
and LC3-II, compromising autophagy induction. 193 
 194 
We have previously reported that the deubiquitinase Ataxin-3 stabilizes Beclin-1, and 195 
that loss of Ataxin-3 reduces Beclin-1 levels and impairs autophagosome biogenesis 196 
19. VCP has been reported to bind Ataxin-3 and to stimulate its deubiquitinase activity 197 
towards synthetic substrates in vitro 20-23, and Ataxin-3 together with VCP are 198 
important for nematode survival during pro-longed starvation32. Hence, Ataxin-3-199 
dependent stabilization of Beclin-1 encompasses a potential mechanism to explain 200 
the role of VCP in autophagy initiation. We found that knockdown and inhibition of 201 
VCP decreased levels of both Ataxin-3 and Beclin-1 (Fig. 3a-b, Fig. 3c; input, and 202 
Extended Data Fig. 5a-c) and postulated that a drop in protective deubiquitination by 203 
Ataxin-3 destabilized Beclin-1 in VCP-inhibited cells. To investigate the role of VCP 204 
in Ataxin-3-dependent regulation of Beclin-1, we utilized an Ataxin-3 mutant with 205 
compromised binding ability to VCP (Ataxin-3VCP; Extended Data Fig. 5d) 33. While 206 
the interaction between Ataxin-3 and Beclin-1 is not dependent on VCP (Fig. 3c and 207 
Extended Data Fig. 5e), the binding of Ataxin-3 to VCP seems to increase the ability 208 
of Ataxin-3 to protect Beclin-1 from proteasomal degradation, as overexpression of 209 
Ataxin3VCP was less able to stabilize Beclin-1 levels compared to overexpression of 210 
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the wildtype Ataxin-3 allele (Fig. 3d-e). These effects are likely proteasome-211 
dependent, as no significant differences were observed between these constructs in 212 
cells treated with the proteasome inhibitor, MG132 (Fig. 3d-e). Similarly, rescue of 213 
LC3 puncta formation (autophagosome numbers) in ATAXIN-3 knockdown cells was 214 
more efficiently accomplished by wild-type Ataxin-3, compared to Ataxin3VCP (Fig. 3f 215 
and Extended Data Fig. 6a-b). Furthermore, we could show that in the presence of 216 
ATP, VCP stimulates Ataxin-3 deubiquitination of Beclin-1 in vitro (Fig. 3g and 217 
Extended Data Fig. 6c). A significant decrease in Beclin-1 ubiquitination was 218 
observed when VCP or Ataxin-3 were added alone (Fig. 3g), but the combination of 219 
the two proteins yielded an even more pronounced reduction in Beclin-1 220 
ubiquitination, hence providing evidence for VCP regulation of Ataxin-3 221 
deubiquitination towards a physiologically relevant substrate. Together, these data 222 
indicate that VCP binding of Ataxin-3 is important to protect Beclin-1 from 223 
proteasomal degradation, by stimulating the deubiquitinase activity of Ataxin-3 224 
towards Beclin-1. Thus, stabilization of Beclin-1 via Ataxin-3 provides one possible 225 
mechanism for VCP-dependent regulation of autophagosome formation. 226 
 227 
VCP interacts with PI3K complex  228 
Beclin-1 is a core component of the PI3K complex, which exists in at least three 229 
different compositions to regulate autophagy at different steps, and endocytosis 34. 230 
The core components VPS15, VPS34 and Beclin-1 form PI3K complex I together 231 
with ATG14L to regulate autophagosome formation, while in complex II ATG14L is 232 
replaced by UVRAG to positively regulate endocytosis 35,36. In complex III, Rubicon 233 
binds UVRAG to negatively regulate the activity of the complex 37,38. We found that 234 
endogenous VCP interacts with all three PI3K complexes (Fig. 4a), as it could be 235 
identified in immunoprecipitations of endogenous ATG14L, UVRAG as well as 236 
Rubicon. We therefore focused further studies on the ATG14L-containing complex I 237 
to gain insights into the role of VCP in autophagosome formation. VCP interacted 238 
with ATG14L even in cells where expression of ATAXIN-3 or BECLIN-1 had been 239 
reduced by siRNA-mediated knockdown (Fig. 4b-c), and Ataxin-3 was found 240 
associated with the ATG14L-containing PI3K complex even when Beclin-1 levels 241 
were diminished (Fig. 4d). Thus, we considered roles for VCP in PI3K complex I 242 
assembly, as a distinct role from its ability to stabilize Beclin-1 levels. 243 
 244 
Knockdown of VCP reduced the amount of total ATG14L as well as the amount of 245 
ATG14L associated with Ataxin-3 (Extended Data Fig. 7a). The reduced levels of 246 
ATG14L could be an indirect effect of decreased Beclin-1 levels, as the PI3K 247 
 
 8 
complex members are known to stabilize each other 38,39. Thus, while our previous 248 
data showed no effect on the Ataxin-3 and Beclin-1 interaction upon VCP inhibition 249 
(Fig. 3c), VCP might enhance the recruitment of Ataxin-3 to the pool of Beclin-1 in 250 
complex with ATG14L. The interaction of VCP with the PI3K complex I seems 251 
independent of Ataxin-3 and Beclin-1, suggesting that VCP can interact with 252 
additional components of the PI3K complex. In agreement with this, we found that 253 
VCP interacts directly with VPS34, ATG14L and Beclin-1 of the PI3K complex I in 254 
vitro (Extended Data Fig. 7b-d; VPS15 was not included as it could not be 255 
individually purified), further indicating that VCP could interact with the PI3K complex 256 
in the absence of Ataxin-3. A mutated version of the VCP cofactor UFD1L, 257 
UFD1LVCP (aa215-241; 40), was used as a negative control in binding experiments.  258 
 259 
VCP regulates PI3K assembly in vitro and in vivo 260 
Addition of VCP to pre-assembled PI3K complexes (Extended Data Fig. 8a) 261 
increased the in vitro production of PI(3)P (Fig. 4e), suggesting that we should test if 262 
VCP facilitates the assembly of the PI3K complex itself, in addition to bringing Ataxin-263 
3 close to Beclin-1. In agreement with a role for VCP in regulating PI3K assembly, 264 
knockdown of VCP expression decreased the interaction between ATG14L (as a 265 
surrogate for PI3K complex I) with the PI3K components Beclin-1 and VPS34 266 
(Extended data Fig. 8b-c). Similarly, inhibition of VCP ATPase activity also interfered 267 
with the interaction of ATG14L with the PI3K components VPS15, VPS34 and Beclin-268 
1 (Fig. 5a-b), as well as with the binding of VCP itself to ATG14L, indicating that the 269 
presence and activity of VCP is aiding PI3K assembly. When analyzing the amount 270 
of VCP pulled down by endogenous ATG14L after VCP inhibition, we detected two 271 
bands for VCP: one around 100 kDa as expected for endogenous VCP and one 272 
band slightly above. This band may be a post-translationally modified version of VCP 273 
that is enriched in the interaction with PI3K, and since it could be detected also in the 274 
input (Extended data Fig. 8d, long exposure) and was affected by siRNA against 275 
VCP (Extended data Fig. 8e), both VCP bands were included in quantifications. Of 276 
the VCP inhibitors used, CB-5083 was the only inhibitor that did not cause a clear 277 
trend of decreased interactions of PI3K complex I components with ATG14L (Fig. 5a-278 
b), perhaps related to it only inhibiting the D2 ATPase activity of VCP, whereas the 279 
other inhibitors affect both ATPase domains 41,42. 280 
 281 
We further demonstrated that VCP directly acts to enhance the assembly of 282 
individually purified components into complete PI3K complexes in vitro, as co-283 
purification with ATG14L was increased for all the PI3K components when VCP was 284 
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present (Fig 5c-d, Extended data Fig. 8f). Thus, the binding of VCP to PI3K 285 
components enhances the assembly of fully formed complexes in a manner that 286 
requires VCP ATPase activity. 287 
 288 
Discussion 289 
In this study, we identify two unforeseen functions for VCP in autophagy initiation. 290 
First, VCP binds both Ataxin-3 and Beclin-1 in the PI3K complex, thereby enhancing 291 
the deubiquitination and stabilization of Beclin-1 (Fig. 5e; left). Thus, inhibition or 292 
knockdown of VCP decreases levels of Beclin-1 and inhibits autophagy. Second, 293 
VCP interacts with multiple components of the Beclin-1-containing PI3K complex and 294 
enhances complex assembly and resultant kinase activity, increasing the production 295 
of the autophagy signaling lipid PI(3)P (Fig. 5e; right). Inhibition of VCP ATPase 296 
activity blocks both functions, indicating that both roles of VCP require ATP 297 
hydrolysis. As VCP interacts in a binary fashion with the components of the complex, 298 
it may be simply acting as a scaffold to enhance complex formation. It is possible that 299 
this process may be driven by ATP-dependent conformational changes (as it is 300 
blocked by VCP inhibitors), or by bridging the kinase and substrate contact, as VCP 301 
have been suggested to bind lipids such as phosphoinositols 43,44. 302 
 303 
The link between VCP and Ataxin-3 activity had been previously established in vitro 304 
23, and the two proteins have been implicated in promoting autophagy where Ataxin-3 305 
was found also to interact with the autophagosome protein LC3 32. While our data 306 
provides a link between these two findings, and show that VCP and Ataxin-3 acts to 307 
stimulate Beclin-1 levels to promote autophagy, it remains to be determined whether 308 
VCP also influences the proposed interaction between Ataxin-3 and LC3 and if this is 309 
yet another mechanism whereby VCP could influence autophagy initiation.  310 
 311 
Studies on the role of VCP in autophagy have thus far been focused on its role in 312 
autophagosome maturation, as the defect in autophagosome formation is masked by 313 
the strong maturation phenotype seen when reducing VCP levels or activity. We 314 
overcame this issue by combining an initial inhibition of lysosome fusion with a 315 
subsequent acute inhibition of VCP activity using three different VCP specific 316 
inhibitors (DBeQ, NMS873 and CB-5083) to detect a decrease in autophagosome 317 
marker LC3. Initial disruption of lysosomal fusion before addition of VCP inhibitors 318 
was crucial to avoid the consequences of VCP inhibition on lysosomal function. With 319 
simultaneous administration of lysosome and VCP inhibitors, VCP inhibitors could 320 
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exert their function on autophagosome maturation before lysosomal inactivation 321 
occurred, thus leading to an accumulation of LC3-positive autophagosomes 16. 322 
 323 
Utilizing chemical VCP inhibitors, we were further able to see a decrease in PI(3)P 324 
production and the subsequently reduced recruitment of early autophagy markers. 325 
Thus, the acute inhibition of VCP provided us with a tool to characterize a role for 326 
VCP in autophagy initiation which had previously gone unrecognized in genetic 327 
knockdown experiments. The use of inhibitors also allows one to readily assess if 328 
effects are simply due to inert protein or due to its ATPase activity. Our proposed 329 
model for VCP regulating PI(3)P production could potentially comprise an additional 330 
mechanism for the block in autophagosome maturation seen upon reduced VCP 331 
activity. As PI(3)P also plays an important role in endosomal membrane fusion and 332 
endocytic trafficking 45, it provides a possible mechanism whereby VCP activity could 333 
influence both autophagy initiation and maturation. 334 
 335 
Mutations in the essential VCP gene have been linked to multisystem disorders 336 
including Inclusion body myopathy with early-onset Paget disease and 337 
frontotemporal dementia (IBMPFD) and neurogenerative diseases such as 338 
Parkinson’s disease and Amyotrophic lateral sclerosis (ALS)  10,46,47. It is possible that 339 
the different aspects of these disorders are linked to the diverse functions of VCP, 340 
and that some could be explained by a decreased ability for autophagy induction as 341 
described by our data. For instance, mutations in VCP affecting ATPase activity has 342 
been linked to an increased abundance of pathologic tau fibrils and the development 343 
of frontotemporal degeneration 48, and while this could be an effect of impaired 344 
disaggregase activity of VCP 49 it Is also feasible that the accumulation of tau could 345 
be due to a decline in VCP-dependent autophagic capacity, since tau is an 346 
autophagy substrate. 347 
 348 
It remains to be determined how the temporal and local recruitment of VCP to PI3K is 349 
regulated. Our observation that VCP co-purified with ATG14L runs as two bands on 350 
a western blot indicates the possibility of posttranslational regulation of VCP. ULK1 351 
and ULK2 are two upstream kinases known to regulate autophagy that 352 
phosphorylate VCP to regulate the disassembly of heat-induced stress-granules 50, 353 
and thus encompass potential candidates for upstream regulation, although this 354 
needs to be further investigated in future studies. Furthermore, it remains to be 355 
elucidated which (if any) of the known VCP cofactors are important for this proposed 356 




In conclusion, our findings add to the complexity of the cellular functions of VCP and  359 
provides evidence for its role as an important regulator of autophagy initiation.  360 
 361 
Online Methods 362 
 363 
EXPERIMENTAL MODELS 364 
Cell Lines 365 
Human cervical epithelium HeLa (ATCC; #CCL-2; CVCL_0030), and human 366 
embryonic kidney cell line HEK293 (ECACC; #85120602) were cultured in 367 
Dulbecco’s modified Eagle’s medium (DMEM) (4.5 mg/L of glucose; Sigma) 368 
supplemented with 10% FBS (Sigma), 2mM L- glutamine (Sigma) and 100 U/mL 369 
penicillin and 100 mg/mL streptomycin (Sigma). Human embryonic suspension cells, 370 
Expi293F (Gibco; #A14527), were grown in Expi293 Expression Medium (Gibco) 371 
All cell lines were maintained at 37℃ and 5% CO2 and were regularly tested for 372 
mycoplasma contamination. All cell lines are of female origin (HeLa, HEK293, 373 
Expi293F). For starvation experiments using cell lines, cells were washed three times 374 
in starvation media (Hank’s balanced salt solution (HBSS, Invitrogen) or Earle’s 375 
balanced salt solution (EBSS, Sigma) and incubated for 2-4 h at 37°C. 376 
Mouse primary neurons  377 
All animal studies and procedures were performed with project licenses granted by 378 
the UK Home Office and with the approval of the University of Cambridge committee 379 
for animal studies. Primary cortical neurons were isolated from C57BL/6 mice 380 
(Jackson Laboratories) embryos of mixed sex at E16.5 as previously described 19. 381 
Briefly, embryo brains were harvested and placed in PBS/glucose where the 382 
meninges were removed, and the cerebral cortices were dissected. After mechanical 383 
dissociation using sterile micropipette tips, dissociated neurons were resuspended in 384 
PBS+glucose and collected by centrifugation. Viable cells were seeded on poly-385 
ornithine-coated 12-multiwell plates. Cells were cultured in Neurobasal medium 386 
(Thermo Fisher Scientific) supplemented with 2 mM glutamine, 200 mM B27 387 
supplement and 1% Penicillin-Streptomycin at 37°C in a humidified incubator with 388 
5% CO2. One half of the culture medium was changed every two days until 389 
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treatment/infection. After 5 days of ex vivo culturing, differentiated neurons were 390 
treated with different drugs.  391 
 392 
METHODS DETAILS 393 
Antibodies and Reagents 394 
The following primary antibodies have been used in this work: mouse anti-Flag M2 395 
(1:1000), and rabbit anti-Actin (RRID AB_476693; 1:1000) from Sigma Aldrich; rabbit 396 
anti-VCP (RRID: AB_259529; 1:2000), rabbit anti-LC3B (RRID: AB_10003146; 1:400 397 
for IF), rabbit anti-GFP (RRID:AB_305564; 1:1000), mouse anti-GFP (RRID: 398 
AB_298911; 1:1000), rabbit anti-RUBICON (RRID: AB_2827795; 1:1000), rabbit anti-399 
VPS15 (RRID: AB_11141464; 1:1000), Rabbit anti-VPS34 (RRID: AB_2827796; 400 
1:1000), mouse-anti-GAPDH (RRID: AB_2107448; 1:1000), and mouse-anti-WIPI2 401 
(RRID: AB_105459; 1:100 for IF) from Abcam; rabbit anti-LC3B (RRID: 402 
AB_10003146; 1:1000) from Novus Biologicals; mouse anti-Ataxin-3 (RRID: 403 
AB_2129339; 1:1000) from EMD Millipore; rabbit anti-Beclin-1 (RRID: AB_490837; 404 
1:1000), rabbit anti-UVRAG (RRID: AB_2687988; 1:1000); rabbit anti-ATG12 (RRID: 405 
AB_2059086; 1:1000) and rabbit anti-ATG16 (RRID: 8089s 1:100 for IF) from Cell 406 
Signaling; rabbit anti-ATG14L (RRID: AB_1953054; 1:1000), mouse anti-ATG14L 407 
(RRID: AB_10897331; 1:1000) from MBL. VCP inhibitors in DMSO was added to cell 408 
culture media for denoted incubation times: DBeQ (Selleckchem) was used at 10 µM, 409 
NMS873 (Selleckchem) was used at 10 µM, and CB-5083 (Selleckchem) was used 410 
at 2 or 5 µM. The concentrations used in this study was based on previously 411 
established concentrations for cell culture demonstrating a measurable effect on 412 
VCP activity in various cellular functions 51-57. 413 
DNA constructs 414 
The following DNA constructs were used in this study: pCMV6-FLAG-Myc 415 
(PS100001) and pMyc-FLAG-UFD1L (RC202989) from Origene; p3XFLAG-Beclin-1 416 
(#24388), p3XFLAG-Ataxin-3 (#22126), pUbiquitin-HA (#18712), pStrep-Strep-417 
FLAG-VPS15 (#99326), and pStrep-Strep-FLAG-VPS34 (#99327), pFLAG-Beclin1 418 
(FL) (#24388), pFLAG-Beclin1 (1-150) (#24389), pFLAG-Beclin1 (151-241) 419 
( #24390), pFLAG-Beclin1 -(151-241) (#24393), pFLAG-Beclin1 (1-242) (#24391), 420 
pFLAG-Beclin1 (243-450) (#24392). p3XFLAG-ATG14L was a gift from Zhenyu Yue 421 




Trans IT-2020 reagent (Mirus) was used for DNA transfection, while Lipofectamine 424 
2000 (Invitrogen) was used for siRNA transfections, according to the manufacturer’s 425 
instructions. For protein production in HEK293 cells, TransIT-293 (Mirus) was used 426 
according to the manufacturer’s instruction. For protein production in suspension 427 
Expi293F cells, transfection was performed with Polyethylenimine (PEI), at a ratio of 428 
3:1 PEI:DNA. After transfection, cells were maintained in full medium. For 429 
knockdown experiments, cells were transfected with either a single or double round 430 
of 50 nM siRNA (Dharmacon; smartpool siRNA or single oligos). In single 431 
transfections (VCP and BECLIN-1 knockdown), cells were split 24-48 h after 432 
transfection, and harvested 3 days post transfection. For knockdown of VCP for 433 
immunofluorescence, cells were transfected with 25 nM siRNA in suspension and 434 
plated at low density directly onto coverslips, followed by treatment and imaging after 435 
48 h. For double transfections (ATAXIN-3 knockdown), cells were transfected on day 436 
1 and day 3. Cells were split twice, once after each transfection, and harvested 5 437 
days after first transfection. 438 
Western Blot Analysis 439 
Cells were lysed in Laemmli sample buffer and boiled for 10 min at 100°C, separated 440 
by SDS-PAGE, transferred to PVDF membranes and developed with primary and 441 
secondary antibodies. Primary antibodies were used with overnight incubation at 442 
4°C, unless otherwise stated, and the secondary antibodies are used at a 443 
concentration of 1:2000 and incubated for 1 h at room temperature. For 444 
immunoprecipitation experiments, light-chain specific secondary antibodies were 445 
used at a 1:1000 dilution for 1 h at room temperature. Blots were developed using an 446 
ECL enhanced chemiluminescence detection kit (GE Healthcare), or with direct 447 
infrared fluorescence detection on an Odyssey Infrared Imaging System. Western 448 
blots in main Figures 1a-c. 1h, 3a, 3c-e, 4a-c, and figures in extended data 1e, 3c, 449 
5a, 5d, 5g, 5a and 6f were developed with chemiluminescence, while the other blots 450 
were developed with fluorescence (LICOR Odyssey system). Densitometric analysis 451 
on the immunoblots was performed using IMAGE STUDIO Lite software, which 452 
enables quantitative analysis of blotting signals. 453 
Mutagenesis 454 
3X-FLAG-Ataxin-3 (addgene #22126) was used as a template to mutate the VCP 455 
binding site and generate Ataxin-3VCP (282-285 RKRR/ANAA). Mutagenesis was 456 
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performed using QuikChange Multi Site-Directed MutagenesisKit (Agilent) and primer 457 
SMH17:  458 
(5’-CTTACTTCAGAAGAGCTTGCGAATGCAGCAGAAGCCTACTTTGAAAAG-3’) 459 
according to manufacturer’s instructions. Myc-FLAG-UFD1L plasmid (Origene 460 
RC213180) was used as template to mutate the VCP binding site and generate 461 
UFD1LVCP (215-241) using QuikChange Site-Directed Mutagenesis Kit (Agilent) 462 
and the following primers: Fw: 5’-GTAGAGCCCAGCCCCTCC-3’; Rev: 5’-463 
GGCTTCACCTTCTGTCGACTC-3’. All constructs were verified by sequencing. 464 
Immunofluorescence 465 
Staining of PI(3)P was performed as described previously58. Briefly, cells on 466 
coverslips were fixed in 2% paraformaldehyde and permeabilized with 20 μM 467 
digitonin in buffer A (20 mM Pipes pH 6.8, 137 mM NaCl, 2.7 mM KCl). Cells were 468 
blocked with buffer A supplemented with 5% (v/v) FBS and 50 mM NH4Cl. Mouse-469 
anti-PI(3)P antibody (1:400; 1 h at room temperature) (Echelon) and secondary 470 
antibody (1:400; 30 min at room temperature) (goat-anti-mouse Alexa Fluor 555; 471 
Thermo Scientific) were applied in buffer A with 5% FBS. Cells underwent post-472 
fixation for 5 min in 2% paraformaldehyde, followed by 2X washes in PBS containing 473 
50 mM NH4Cl, and 1X wash with water before being mounted on microscope slides 474 
with ProLong Gold Antifade Mountant with DAPI (Thermo Scientific). For imaging of 475 
LC3 puncta, cells were fixed in ice cold methanol for 5 min, blocked in 1% BSA at 476 
room temperature for 1 h, permeabilized with 0,5% Triton X-100 for 5 min, then 477 
incubated with rabbit-anti-LC3B (abcam) overnight, and with secondary goat-anti-478 
rabbit Alexa Fluor 647 for 1 h at room temperature. Imaging was conducted with 479 
LSM880 Zeiss confocal with 63X oil-immersion lens. For WIPI2 and ATG16 staining, 480 
cells were fixed in paraformaldehyde 4% for 10 minutes and permeabilized with 0.2% 481 
Triton X-100 for 10 minutes, then incubated with rabbit-anti-ATG16 (Cell signaling) 482 
and mouse-anti-WIPI2 (Abcam) for 1 h at room temperature, and with secondary 483 
goat-anti-rabbit Alexa Fluor 647 and goat-anti-mouse Alexa Fluor 488 for 1 h at room 484 
temperature. Imaging was conducted with LSM710 Zeiss confocal with 63X oil-485 
immersion lens. 486 
Protein Purification 487 
Purification of VCP-GST from E. coli: Expression vector was transformed into 488 
bacterial strain Rosetta BL21 (DE3) (Novagen) according to instructions from 489 
supplier. Cells from a 1 L culture were harvested after overnight induction of protein 490 
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expression with 0.2 mM IPTG at 18°C. Cell pellet was resuspended in 2XPBS 491 
containing protease inhibitors and lysed by incubation with 0.5 mg/mL lysozyme for 492 
30 min on ice, followed by sonication. Lysate was clarified by ultracentrifugation (100 493 
000xg for 15 min at 4°C), and incubated with 1 mL glutathione sepharose resin 494 
(Pierce) for 2 h at 4°C. Resin was washed in a gravity flow column: 5X in 2XPBS and 495 
5X in 2XPBS containing 0,1% Triton X-100 and 1 mM ATP. Purified protein was 496 
either cross-linked to beads for in vitro binding assays or eluted from beads by 497 
cleaving GST-tag with PreScission Protease. For crosslinking, beads were washed 498 
3X in 200 mM HEPES (pH 8.5), and incubated with crosslinking solution (20 mM 499 
dimethyl pimelimidate in 200 mM HEPES pH 8.5) in RT for 60 min. Reaction was 500 
stopped by incubating beads with 0.2 M ethanolamine-HCl (pH 8.2) for 60 min. 501 
Beads were washed 3X in washing buffer (150 mM NaCl, 200 mM Glycine-HCl pH 502 
2.0) and stored in binding buffer (25 mM HEPES pH 7.25, 200 mM NaCl, 0.01% 503 
Triton X-100, and 5% Glycerol, 1 mM DTT) containing 0.05% sodium azide. 504 
For removal of GST tag, beads were washed 5X with PreScission cleavage buffer 505 
(50 mM Tris pH 7.0, 150 mM NaCl, 1mM EDTA, 1mM DTT, Triton X-100 0,01%), and 506 
resuspended in 475 L cleavage buffer. 25 L of PreScission protease was added 507 
and lysate was incubated overnight at 4°C, followed by collection of supernatant 508 
containing purified VCP. 509 
Purification of FLAG-tagged PI3K complexes from HEK293: 10 g of each plasmid 510 
(pStrep-Strep-FLAG-VPS15, p-Strep-Strep-FLAG-VPS34, 3X-FLAG-ATG14L and 511 
3XFLAG-Beclin-1) and 75 l of TransIT-293 used to transfect HEK293 cells in one 14 512 
cm2 poly-D-lysine coated dish. Cells were lysed 3 days post transfection in 1 mL lysis 513 
buffer CelLytic M (Sigma). Clarified lysates were incubated with 100 L of M2 FLAG 514 
agarose resin (50% slurry) at 4°C for 2 h. Beads were added to a gravity flow column 515 
and washed 1X with lysis buffer, 10X with TBS and eluted in 100 L TBS with FLAG 516 
peptides (150ng/L) at 4°C 2 h. For purification of individual PI3K components, cells 517 
were transfected with 30 g of the individual expression plasmid and purified using 518 
the same procedure with an additional washing step with high salt TBS (0.8 M NaCl) 519 
to remove the other complex components.  520 
Purification of FLAG-VPS15 and FLAG-VPS34 from suspension cells: Expi293F 521 
suspension cells were grown to 2,5x106 cells/mL in 500 mL of Expi293 Expression 522 
Medium (Gibco). Cells were transfected with 0,9 mg of pStrep-Strep-FLAG-VPS15 523 
(addgene #99326) and 0,6 mg pStrep-Strep-FLAG-VPS34 (addgene #99327) and 524 
4.5 mg Polyethylenimine 40K (Polysciences, Inc). On the day after transfection, 525 
 
 16 
culture was expanded to 1 L, and 3.3 mM valproic acid (Sigma) and 10 mg/mL 526 
Penicillin/Streptomycin (Sigma) was added. Cells were lysed 3 days post transfection 527 
by homogenization in 50 mL Buffer A (50 mM HEPES pH 7.5; 200 mM NaCl; 5% 528 
glycerol; protease inhibitors) with 0.1 % CHAPS. Lysates were clarified by 529 
centrifugation at 100 000xg and incubated with 1,5 mL packed agarose M2 anti-530 
FLAG resin (Sigma) for 2 h at 4°C. Resin was washed 3X with Buffer A, 3X with 531 
Buffer A with higher salt concentration (800 mM), and additional 4X in buffer A (200 532 
mM NaCl). Proteins were eluted in fractions by incubation (4x60 min) with buffer A 533 
containing 150 ng/l 3XFLAG peptides (Sigma). Purified proteins were analyzed on 534 
gel together with BSA standard to determine protein concentration. 535 
Immunoprecipitation (IP) 536 
For immunoprecipitation of endogenous proteins, cells from one 14 cm2 dish were 537 
lysed in 0,2 mL of IP buffer (20 mM Tris pH 7.4; 2 mM MgCl2; 200 mM NaCl; 538 
protease inhibitors) with 0,5% NP40, cleared by centrifugation, diluted to 1 mL by 539 
addition of IP lysis buffer (final 0,1% NP40). Lysates were pre-cleared for 1 h by 540 
incubation with non-targeting IgG control antibody (mouse-anti-HA or rabbit-anti 541 
GFP) and beads for 2 h at 4°C. Input samples were collected and lysates were then 542 
incubated with primary antibodies overnight at 4°C, followed by the addition of 30 L 543 
of washed beads (50% slurry). Sepharose Protein A beads (GE healthcare) were 544 
used for the immunoprecipitation of endogenous Beclin-1, Ataxin-3 and VPS34, 545 
whereas endogenous ATG14L, UVRAG and Rubicon were immunoprecipitated using 546 
magnetic Dynabeads Protein A (Invitrogen). Beads were washed 3X in lysis buffer 547 
and proteins were eluted in Laemmli sample buffer by boiling and analyzed by 548 
western blot. Endogenous immunoprecipitations were detected with light chain 549 
specific antibodies to avoid interference of heavy chain signal, and ratios in 550 
endogenous IPs were normalized to input to correct for any differences in input 551 
levels. For immunoprecipitation of FLAG-tagged Ataxin-3, cells from 2 wells of a 6-552 
well plate were transfected with 1 g of 3X-FLAG-Ataxin-3 plasmid (Addgene 553 
#22126) each and lysed 1 day post transfection in 100 L IP buffer with 0,5% NP40. 554 
The pooled lysate was diluted and pre-cleared as described above and incubated 555 
with 10 L of magnetic anti-FLAG beads (Sigma) for 2 h at 4°C, followed by washing 556 
and elution into sample buffer.   557 
In vitro binding assay with VCP-GST 558 
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VCP-GST was purified from E. coli and cross-linked to glutathione sepharose beads 559 
(Pierce). Empty glutathione beads were used as a control and buffer composition 560 
and incubation conditions were optimized to minimize interaction with empty beads 561 
and negative control (FLAG-UFD1VCP). 20 L of VCP-GST cross-linked to beads 562 
was incubated with 150-250 ng of FLAG-tagged PI3K proteins in 500 L binding 563 
buffer (25 mM HEPES pH 7.25, 200 mM NaCl, 0.01% Triton X-100, and 5% Glycerol, 564 
1 mM DTT) for 4 h at 4°C. Beads were then washed 4X in binding buffer + 0,1% 565 
Tween-20, and bound proteins were eluted in Laemmli sample buffer and analyzed 566 
by western blot.  567 
In vitro PI3K assembly 568 
Individual FLAG-tagged proteins (ATG14L and Beclin-1 purified from HEK293; 569 
VPS15 and VPS34 purified together from Expi293F suspension cells). 250 ng of 570 
each protein was used per reaction, with the exception of VPS34 which was in 5-10X 571 
excess compared to VPS15. PI3K proteins were incubated in 500 L binding buffer 572 
in the presence or absence of 500 ng VCP (purified, GST tag removed by 573 
PreScission cleavage) for 2 h at 4°C. Assembled PI3K complexes were 574 
immunoprecipitated using mouse-anti-ATG14L antibody (MBL). 1,5 L of primary 575 
antibody was added to the reactions, incubated for 1 h at 4°C followed by the 576 
addition of 15 L Protein A Dynabeads. After 2 h, beads were washed 3X in binding 577 
buffer and proteins were eluted in sample buffer. 578 
In vitro Deubiquitination assay 579 
Ubiquitinated Beclin-1 was purified from HeLa cells overexpressing 3X-FLAG-Beclin-580 
1 together with HA-Ubiquitin (1:3), treated with proteasome inhibitor MG132 at 10 M 581 
and 10 M deubiquitinase inhibitor PR619 for 6 h, using FLAG M2 magnetic beads. 582 
1/10 of the amount of Beclin-1-ubq purified from HeLa in a 14 cm2 plate was mixed 583 
with 55 ng of recombinant active VCP-GST (SignalChem) and 12.5 ng of Ataxin-3-584 
GST (BostonBiochem) in 21 L deubiquitination buffer (Tris pH 8.8 50 mM; NaCl 10 585 
mM; EDTA 1mM; Glycerol 5%) with or without 4 mM of ATP and incubated at 37°C 586 
for 5 h. The reaction was stopped by addition of 4 L 4X Laemmli sample buffer. 587 
Ubiquitination was analyzed by western blot using antibody against ubiquitin-HA. 588 
Levels of Beclin-1, VCP and Ataxin-3 were analyzed on a separate blot. 589 
 590 
Proteomic analysis of Beclin-1 interactors from brain lysate 591 
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C57BL/6J mice (Jackson Laboratories) at the age of 6 weeks were sacrificed by a 592 
schedule 1 method. The brain was collected and frozen for western blot analysis. 593 
Brain tissues were dissected, homogenized and resuspended in tissue lysis buffer on 594 
ice (50mM Tris pH 7.4, 0.5% Triton X-100 and protease inhibitor cocktail) and the 595 
supernatant was centrifuged twice. Brain lysates were incubated with Beclin-1 596 
antibody (Cell Signaling) or isogenic rabbit IgG control overnight at 4°C followed by 2 597 
h incubation with protein A sepharose beads (GE Healthcare). The 598 
immunocomplexes were then washed with lysis buffer three times. Samples were 599 
resolved into a Novex pre-cast 4-12% Bis-Tris polyacrylamide gel (Thermo Fisher 600 
Scientific). The lanes were excised and cut in 3 approximately equal chunks and the 601 
proteins reduced, alkylated and digested in-gel. The resulting tryptic peptides 602 
analyzed by LC-MSMS using a Q Exactive coupled to an RSLCnano3000 (Thermo 603 
Scientific). Raw files were processed in Proteome Discoverer 1.4 using Sequest to 604 
search a mouse Uniprot database. Peptides were filtered to high confidence (0.01 605 
FDR) using Percolator. 606 
 607 
In vitro PI(3)P kinase assay 608 
FLAG-tagged PI3K components were co-expressed and purified from HEK293 cells 609 
using M2 FLAG agarose beads (Sigma). PI3K complexes on agarose beads were 610 
used in in vitro kinase reaction. In vitro kinase reaction and PI(3)P detection was 611 
performed using Class III PI3K Elisa Kit (Echelon). 1/10 of PI3K complexes purified 612 
from one 14cm2 dish was used per kinase reaction. Complexes were added to tubes 613 
containing kinase buffer (20 mM Tris, 20 mM NaCl, 5mM MgCl2, 10 mM MnCl2, 1 mM 614 
EDTA, 50 M DTT, 0,02% CHAPS) with 0.1 mg/mL sonicated PI substrate, in the 615 
presence or absence of 10 ng purified VCP protein (50 l final reaction volume). 616 
Reactions were started by the addition of 50 M ATP and allowed to continue for 2 h 617 
at 37°C before being stopped by the addition of 5 L of 100 mM EDTA and upon 618 
centrifugation, supernatants were transferred to 96-well plates for detection of PI(3)P 619 
using instructions for the Class III PI3K Elisa Kit with the following alterations: 620 
incubation with PI(3)P detector was reduced to 50 min, and incubation with TMB 621 
buffer for developing was extended to 45 min. Upon signal development, plates were 622 
read at 450 nM using Spark microplate reader (Tecan). 623 
 624 
QUANTIFICATION AND STATISTICAL ANALYSIS 625 
Image Analysis 626 
 
 19 
Puncta analysis (PI(3)P and LC3) was performed in ImageJ, with manual annotation 627 
of cell boundaries using ROI and automatic analysis of number of puncta per cell 628 
using particle analysis plugin, using the same cut-off for puncta identification in all 629 
conditions. A minimum of 60 cells was examined for each condition and experiments 630 
were repeated at least three times. For WIPI2 and ATG16L puncta analysis, 631 
Cellprofiler software was used. Cell boundaries were determined based on the 632 
fluorescence of the proteins analyzed. Automatic analysis of the number and area of 633 
the puncta per cell were obtained using IdentifyPrimeryObjects. Same settings were 634 
used for the analysis of the puncta in all conditions. Western blots images were 635 
quantified by densitometry analysis using ImageStudio Lite software. 636 
Statistical analysis 637 
Significance levels for comparisons between groups were determined with unpaired 638 
students t-test or one-way ANOVA for multiple comparisons using GraphPad Prism 8 639 
(GraphPad Software) or Excel (Microsoft office). For western blots, protein levels 640 
were normalized to total forms or a housekeeping protein, such as actin or GAPDH. 641 
All data is expressed as means ± standard deviation (SD), unless otherwise stated in 642 
figure legends. P values of < 0.05 were considered statistically significant. The 643 
experiments were appropriately randomized and blinded when possible. More 644 
information on statistical analysis is given in figure legends. 645 
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Authors can confirm that all relevant data are included in the paper and/or its 647 
supplementary information files. Further information and requests for resources and 648 
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Figure legends 880 
 881 
Figure 1. VCP interacts with Beclin-1 and regulates autophagy initiation 882 
(a) Immunoprecipitation of endogenous Beclin-1 from HeLa cells (two replicates, a 883 
and b).  (b, c) DBeQ increases LC3-II levels in DMSO conditions, but decreases 884 
upon treatment with Bafilomycin A1 (BafA; 400 nM) in basal conditions (b; n=3, -BafA 885 
p=0.0009, +BafA p= 0.0328) and in HBSS starvation conditions (c; n=3, -BafA p= 886 
0.0005, +BafA P= 0.0005). Cells were treated with BafA for 1 h prior to addition of 10 887 
M DBeQ (5 h) in basal media or starvation (HBSS). Graphs represent LC3-II/actin 888 
ratios, normalized to DMSO control. (d, e) DBeQ impairs starvation-induced 889 
autophagy. HeLa cells were pretreated with BafA (2 h), before transition to starvation 890 
media (HBSS) with BafA, combined with addition of DMSO or 10 M DBeQ (3 h); 891 
n=4, number of cells counted: 30-65 per condition, DMSO vs HBSS p= 0.0201, 892 
HBSS vs HBSS+DBeQ p=0.0474. Representative images of immunofluorescence 893 
analysis of LC3 puncta formation during starvation shown in (e). (f) VCP inhibition 894 
impairs formation of PI(3)P puncta upon starvation. HeLa cells were pretreated with 895 
10 M DBeQ or with wortmannin (Wm; 1M) prior to starvation (HBSS 1 h); n=3, 896 
number of cells counted: 40-60 per condition, DMEM vs HBSS p= 0.0025, HBSS vs 897 
HBSS+DBeQ p= 0.0026, HBSS vs HBSS+Wm p= 0.0036. Representative 898 
microscopy frames shown in Extended data Fig. 2d. (b-d; f) Data in bar graphs 899 
presented as normalized mean ± SD, *p<0.05, **p < 0.005, ***p < 0.0005, unpaired 900 
two-tailed Students t-test. Scale bar = 10 m. See also Extended data Figures 1-3. 901 
 902 
Figure 2. VCP governs the recruitment of early autophagy markers 903 
(a, b) DBeQ reduced accumulation of early autophagy marker WIPI2 during 904 
starvation. HeLa cells in basal media (DMEM) compared to cells subjected to 905 
starvation (HBSS 2 h) in combination with DMSO or DBeQ (10 M). Median area of 906 
WIPI2 signal per cell quantified and normalized to control; n=3, number of cells 907 
counted: 30-40 per condition, DMEM vs HBSS p= 0.0072, HBSS vs HBSS+DBeQ p= 908 
0.0076. Representative microscopy frames shown in (b). (c, d) Inhibition of starvation 909 
induced ATG16 puncta by VCP inhibition. HBSS 2 h, in combination with DMSO or 910 
DBeQ (10 M). Median area of ATG16 per cell quantified and normalized to control, 911 
n=4, number of cells counted: 30-40 per condition, DMEM vs HBSS p= 0.0041, 912 
HBSS vs HBSS+DBeQ p= 0.02656. Representative microscopy frames shown in (d).  913 
(a, c) Bar graphs data presented as normalized mean ± SD. *p<0.05, **p < 0.005, 914 
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unpaired two-tailed Students t-test. Scale bar = 10 m. See also Extended data 915 
Figure 4. 916 
 917 
 918 
Figure 3. VCP regulates Beclin-1 levels by stabilization and activation of 919 
Ataxin-3 920 
 (a)  Beclin-1 levels in primary mouse neurons after DBeQ (10 µM) treatment for 5 h; 921 
n=3, p< 0.0001.(b) Beclin-1 levels in HeLa cells after treatment with VCP inhibitor 922 
DBeQ (10 M for 8 h). Cells were co-treated with cycloheximide (CHX, 50 µg/ml) +/- 923 
proteasome inhibitor MG132, n=4, p= 0.0002. (c) Immunoprecipitation of 924 
endogenous Ataxin-3 from HeLa cells, treated with DBeQ (10 M, 5 h), ratio of 925 
Beclin-1 to Ataxin-3 normalized to input levels displayed below graph. Experiment 926 
was repeated twice. (d, e) Beclin-1 levels upon overexpression of Ataxin-3ΔVCP or 927 
wildtype Ataxin-3. Beclin-1-FLAG was overexpressed together with empty vector, 928 
Ataxin-3-FLAG or Ataxin-3ΔVCP-FLAG in the presence of CHX and MG132. 929 
Quantification of Beclin-1 to Actin levels presented in (e); n=4, -MG132: FLAG vs 930 
Ataxin-3 p= 0.00011, Ataxin-3 vs Ataxin-3 ΔVCP p= 0.0014. (f) HeLa cells are treated 931 
with control siRNA or siRNA for ATAXIN-3, followed by reconstitution with Ataxin-3 or 932 
Ataxin-3ΔVCP and subjected to immunofluorescence microscopy. Number of LC3 933 
puncta per cell quantified and normalized to wildtype Ataxin-3; n=3, p= 0.0114. See 934 
also Extended data Fig. 6a-b for microscopy images and scatter plot from a 935 
representative experiment. (g) In vitro deubiquitination of Beclin-1 upon addition of 936 
purified Ataxin-3 with and without addition of purified VCP in the presence or 937 
absence of ATP. Levels of ubiquitinated Beclin-1 were quantified; n=3, +ATP 938 
samples: control vs Ataxin-3 p= 0.01186, control vs Ataxin-3+VCP p= 0.000375, 939 
control vs VCP p= 0.000218, Ataxin-3 vs Ataxin-3+VCP p=0.02173, Ataxin-3+VCP vs 940 
VCP p=0.02836. Representative gel image in Extended data Fig. 6c. (a, b, e-g) Bar 941 
graphs data presented as normalized mean ± SD. *p<0.05, **p < 0.005, ***p < 942 
0.0005, unpaired two-tailed Students t-test. See also Extended data Figure 5 and 6. 943 
 944 
Figure 4. Interaction of VCP with PI(3)P-producing Beclin-1 complexes 945 
(a) Endogenous UVRAG, ATG14L and Rubicon were immunoprecipitated from HeLa 946 
cells. (b) Immunoprecipitation of endogenous ATG14L in cells treated with control 947 
siRNA or siRNA against ATAXIN-3. (c) Immunoprecipitation of ATG14L in control 948 
cells versus cells treated with siRNA against BECLIN-1. (d) Immunoprecipitation of 949 
Ataxin-3-FLAG in cells treated with control siRNA, or siRNA against BECLIN-1. Cells 950 
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in (c-d) overexpress ATG14L (c,d) and ATAXIN-3-FLAG (d), and IP ratios have been 951 
normalized to input ratios to account for difference in input protein levels. (e) In vitro 952 
PI(3)P production by PI3K complexes in the presence of absence of purified VCP. 953 
The VPS34 inhibitor IN1 (1M) was used as a control. Bar graph data presented as 954 
normalized mean ± SD, n=3-4, *p < 0.05, **p < 0.005, ***p < 0.0005, one-way 955 
ANOVA with Fisher's LSD test, PI3K vs VCP p<0.001, PI3K vs PI3K+VCP p=0.005, 956 
PI3K vs PI3K+IN1 p=0.012. See also Extended Data Fig. 7. 957 
 958 
Figure 5. VCP regulates the assembly of PI3K complexes  959 
(a) Immunoprecipitation of endogenous ATG14L from HeLa cells treated with DMSO, 960 
10 M NMS873, 5 M CB-5083 or 10 M DBeQ for 6 h. (b) Amount of proteins co-961 
immunoprecipitated with ATG14L in the denoted conditions, ratioed to the amount in 962 
input sample and normalized to DMSO control; n=4, for NMS873 sample: VCP p = 963 
0.04275, VPS34 p = 0.00410, Beclin-1 p = 0.00263; for CB-5083: Beclin-1 p= 964 
0.04861; for DBeQ: VCP p = 0.019, VPS15 p = 0.00172, VPS34 p = 0.04765, Beclin-965 
1 p = 0.006. (c) In vitro assembly of PI3K complexes. FLAG-tagged PI3K 966 
components were added individually (VPS15 and VPS34 purified and added 967 
together) and incubated alone or together with purified VCP, followed by 968 
immunoprecipitation of ATG14L. (d) Ratios of proteins co-immunoprecipitated with 969 
ATG14L in the denoted conditions in vitro, normalized to ratios in DMSO control; 970 
n=7, VPS15 p = 0.006, VPS34 p = 0.004, Beclin-1 p = 0.025. (e) Schematic 971 
illustrating the dual role of VCP in autophagy initiation. VCP binds Ataxin-3 and 972 
Beclin-1 and stimulates deubiquitination of Beclin-1, and thereby stabilizes Beclin-1 973 
protein levels. VCP also binds to other components of the PI3K complex and 974 
enhances its assembly and activity. Inhibition of VCP with CB-5083, NMS873 or 975 
DBeQ perturbs both functions. (b, d) Bar graphs data presented as normalized mean 976 
± SD. *p < 0.05, **p < 0.005, unpaired two-tailed Students t-test. See also Extended 977 
Data Fig. 8. 978 
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EXTENDED DATA 980 
Extended Data Figure 1. VCP interacts with Beclin-1 in vivo and in vitro.  981 
 (a) Schematic overview of Beclin-1 protein domains; with the N-terminal domain in 982 
dark grey, coiled-coiled domain (CCD) in blue, and the beta-alpha repeated, 983 
autophagy-specific (BARA) domain in light grey. Depicted below is the different 984 
truncation mutants used for binding studies (all with N-terminal FLAG tag). (b) In vitro 985 
binding of FLAG-tagged Beclin-1 truncation mutants to VCP-GST crosslinked to 986 
beads. Empty Glutathione beads and mutated VCP interactor UFD1L (aa215-241; 987 
UFD1LVCP), were used as a negative control in binding experiments. Ratio of bound 988 
protein bound to VCP-GST was quantified by detection of FLAG signal in bound 989 
fraction divided by input signal and normalized to the full-length control; n=5, 990 
UFD1LVCP p= 0.0031. (c) Representative gel of in vitro binding experiment quantified 991 
in (b). (d) DBeQ impairs autophagic flux and autophagosome formation during 992 
starvation (HBSS, 4 h) in primary neurons, as demonstrated by LC3-II levels in 993 
conditions without and with 1 h pre-treatment with Bafilomycin A1 (BafA; 400 nM); 994 
n=3, -BafA p = 0.00105, +BafA p = 0.00005. (b, d) Bar graphs data presented as 995 
normalized mean ± SD, **p < 0.005, ***p < 0.0005, unpaired two-tailed Students t-996 
test. See also main Figure 1. 997 
Extended Data Figure 2. VCP regulates early autophagy initiation.  998 
(a) LC3 puncta formation upon treatment with VCP inhibitors. HeLa cells were 999 
pretreated with BafA (2 h), before transition to HBSS (+ BafA), with addition of 1000 
DMSO, 10 M NMS873 or 5 M CB-5083 for 3 h. Number of LC3 puncta per cell 1001 
normalized to DMEM control; n=3, number of cells counted: 50-60 per condition, one-1002 
way ANOVA with Dunnett's correction for multiple comparisons, DMEM vs 1003 
HBSS+DMSO p = 0.049, HBSS+DMSO vs HBSS+NMS873 p = 0.009, HBSS+DMSO 1004 
vs HBSS+CB-5083 p = 0.012. (b) Size of LC3 puncta during starvation and VCP 1005 
inhibition; n=3. (c) Representative images of LC3 puncta formation, as quantified in 1006 
(a) and (b). (d) Representative images for PI(3)P puncta formation upon starvation 1007 
(HBSS 1 h) in HeLa cells, with and without treatment with the VPS34 inhibitor Wm 1008 
(1M) as quantified in main  Fig.1f. (e) Representative images for PI(3)P puncta 1009 
formation upon starvation (HBSS 1 h) in HeLa cells, with and without treatment with 1010 
10 M NMS873 or 5 M CB-5083 compared to DMSO in basal media (DMEM) as 1011 
quantified in (f, g). (f) Quantification of number of PI(3)P puncta per cell during 1012 
starvation and VCP inhibition normalized to DMEM control; n=4, number of cells 1013 
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counted: 40-50 per condition, one-way ANOVA with Dunnett's correction for multiple 1014 
comparisons:  DMEM vs HBSS p= 0.003, HBSS vs HBSS+NMS873 p < 0,001, 1015 
HBSS vs  HBSS+2 µM CB-5083 p= 0.016, HBSS vs HBSS+5 µM CB-5083 p < 1016 
0,001, HBSS vs HBSS+IN1 p= 0.002. (g) Quantification of size  of PI(3)P puncta per 1017 
cell from experiment in (f); one-way ANOVA with Dunnett's correction for multiple 1018 
comparisons:  HBSS vs HBSS+NMS873 p= 0.033, HBSS vs HBSS+2 µM CB-5083 1019 
p= 0.049, HBSS vs HBSS+5 µM CB-5083 p=0.049, HBSS vs HBSS+IN1 p= 0.026. 1020 
(h) ATG5-ATG12 conjugation in HeLa cells treated with siRNA to knockdown 1021 
expression of VCP; n=3, unpaired two-tailed Student t-test, VCP siRNA 11 p= 1022 
0.0009, VCP siRNA 12 P= 0.0007. (a, b, f-h) Data in bar graphs presented as 1023 
normalized mean ± SD. *p<0.05, **p<0.005, ***p < 0.0005. Scale bar = 10 m. See 1024 
also main Figure 1. 1025 
 1026 
Extended Data Figure 3. Knockdown of VCP affects autophagy initiation 1027 
(a) Knockdown of VCP impairs PI(3)P production upon starvation. HeLa cells treated 1028 
with control siRNA (ctrl) or siRNA targeting VCP were starved (HBSS 1 h) 48 h post 1029 
transfection and stained for nuclei (DAPI, blue), VCP levels (green) and PI(3)P 1030 
production (red). (b) Quantified data for experiment in (a), shown as normalized 1031 
mean ± SD, n= 3, number of cells counted: 40-50 per condition, unpaired two-tailed 1032 
Students t-test, DMEM vs HBSS p= 0.03855, HBSS vs kd VCP p= 0.04527. (c) LC3-1033 
II levels upon VCP knockdown in the absence and presence of BafA (400 nM). 1034 
Efficiency of VCP kd tested in separate blot, before cells were divided into -BafA and 1035 
+BafA conditions. (d) Quantified data for LC3-II levels for experiment in (c), shown as 1036 
normalized mean ± SD, n= 4, -BafA VCP siRNA 11 p= 0.00058, -BafA VCP siRNA 1037 
12 p= 0.00046. *p<0.05, **p < 0.005, ***p < 0.0005. Scale bar = 10 uM. See also 1038 
main Figure 1. 1039 
Extended Data Figure 4. VCP regulates the recruitment of early autophagy 1040 
markers during starvation and mTOR inhibition. 1041 
(a) Immunofluorescent analysis of WIPI2 puncta formation upon starvation with VCP 1042 
inhibition. HeLa cells in basal media (DMEM) compared to cells subjected to 1043 
starvation (HBSS 2 h) in combination with DMSO, 10 M NMS873 or 5 M CB-5083. 1044 
Median area of WIPI2 signal per cell normalized to control; n=5, number of cells 1045 
counted: 30-40 per condition, DMEM+DMSO vs HBSS+DMSO p=0.0076, 1046 
HBSS+DMSO vs HBSS+NMS873 p=0.0223, HBSS+DMSO vs HBSS+CB-5083 1047 
p=0.0253. (b) Immunofluorescent analysis of ATG16 puncta formation upon 1048 
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starvation during VCP inhibition. HBSS 2 h, in combination with DMSO, 10 M 1049 
NMS873 or 5 M CB-5083. Median area of ATG16 per cell normalized to control; 1050 
n=4, number of cells counted: 30-40 per condition, DMEM+DMSO vs HBSS+DMSO 1051 
p=0.0036, HBSS+DMSO vs HBSS+NMS873 p= 0.0033, HBSS+DMSO vs 1052 
HBSS+CB-5083 p=0.0006. (c) Immunofluorescent analysis of LC3 puncta induction 1053 
upon mTOR inhibition by Torin 1. HeLa cells pre-treated with BafA (400 nM) together 1054 
with DMSO, 10 M NMS873 or 5 M CB-5083 for 1 h, were subjected to Torin 1 (1 1055 
M) treatment for 4 h. Median area of LC3 per cell normalized to control; n=3, 1056 
number of cells counted: 30-40 per condition, DMSO vs Torin 1 p= 0.0021, Torin 1 vs 1057 
Torin 1+NMS873 p= 0.0035, Torin 1 vs Torin 1+CB-5083 p= 0.0034. (a-c) Bar graphs 1058 
data presented as normalized mean ± SD, *p<0.05, **p < 0.005, unpaired two-tailed 1059 
students t-test. (d) Representative images of WIPI2 puncta formation upon 1060 
starvation, as quantified in (a). (e) Representative images of ATG16 puncta 1061 
formation, as quantified in (b). (f) LC3 puncta formation upon Torin 1 treatment, as 1062 
quantified in (c). Scale bar = 10 m. See also main Figure 2. 1063 
 1064 
Extended Data Figure 5. VCP regulates levels of Beclin-1 via Ataxin-3. 1065 
(a) Beclin-1 levels in HeLa cells after knockdown of VCP compared to control cells 1066 
transfected with non-targeting siRNA; n=3, VCP siRNA 11 p= 0.00158, VCP siRNA 1067 
12 p<0.0001. (b) Beclin-1 levels in HeLa cells upon treatment with DMSO, 10 µM 1068 
NMS873 or 5 µM CB-5083 for 5 h; n=7, NMS873 p= 0.00013, CB-5083 p= 0.00319. 1069 
(c) Ataxin-3 levels in HeLa cells upon treatment with DMSO, 10 µM NMS873 or 5 µM 1070 
CB-5083 for 5 h; n=3, NMS873 p= 0.0002, CB-5083 p= 0.0055. (a-c) Bar graphs 1071 
represent Beclin-1 or Ataxin-3 to loading control (Actin or GAPDH) ratios displayed 1072 
as mean ± SD normalized to control, *p<0.05, **p < 0.005, ***p < 0.0005, unpaired 1073 
two-tailed students t-test. (d) FLAG-tagged Ataxin-3 or mutated version Ataxin-3 ΔVCP 1074 
were expressed together with VCP-HA, followed by FLAG immunoprecipitation. (e) 1075 
Immunoprecipitation of FLAG proteins from cells expressing empty FLAG, FLAG-1076 
tagged Ataxin-3 or Ataxin-3 ΔVCP. See also main Figure 3. 1077 
 1078 
Extended Data Figure 6. VCP regulates Ataxin-3 deubiquitinase activity 1079 
towards Beclin-1.  1080 
(a, b) Representative experiment from main Fig. 3f: LC3 puncta per cell in HeLa cells 1081 
depleted of Ataxin-3 and reconstituted with wildtype Ataxin-3 or Ataxin-3ΔVCP, n=60-1082 
 
 32 
80 cells analyzed per condition. Scale bar = 10 m. (c) Representative gel image of 1083 
in vitro deubiquitination assay, quantified in main Fig. 3g. See also main Figure 3. 1084 
Extended Data Figure 7. VCP interacts with PI3K complexes in vitro. 1085 
(a) Immunoprecipitation of Ataxin-3-FLAG in control and VCP knockdown cells, 1086 
overexpressing FLAG-Ataxin-3 and ATG14L. IP ratios are normalized to input to 1087 
account for differences in input protein levels. (b) Protein-stained gel with individually 1088 
purified FLAG-tagged PI3K components. (c) Protein-stained gel of VCP-GST purified 1089 
from E. coli and cross-linked to glutathione agarose beads. (d) In vitro 1090 
immunoprecipitation with VCP-GST beads and individually purified PI3K 1091 
components: VPS34, ATG14L, Beclin-1 and UFD1LVCP (aa215-241) as a negative 1092 
control. Experiment was repeated 6 times. 1093 
 1094 
Extended Data Figure 8. VCP interacts with PI3K complex I. 1095 
 1096 
(a) FLAG-tagged PI3K complexes purified from HEK293 cells. Protein-stained gel 1097 
(left) and FLAG-probed western blot (right). (b) Quantification of immunoprecipitation 1098 
of endogenous ATG14L in control cells and in VCP knockdown cells. IP ratios have 1099 
been normalized to input ratios. Representative gel in (c); n=3, unpaired two-tailed 1100 
student t-test, bar graph data presented as normalized mean ± SD, kd VCP Beclin-1 1101 
p=0.0127, kd VCP VPS34 p=0.0041.(d) VCP levels in input samples from 1102 
endogenous immunoprecipitation of ATG14L with short and long exposure (SE and 1103 
LE). VCP upper band denoted by red arrow. (e) Short and long exposures of VCP 1104 
levels from VCP kd experiments. Quantifications shown below blots, normalized to 1105 
levels in control sample. (f) Purification of FLAG-VPS15 and FLAG-VPS34 from 1106 
293Expi cells. Purified proteins are visualized with protein stain (instant blue; left 1107 
lane) and by western blot analysis using FLAG antibody (middle lane). The same 1108 
membrane was cut and probed with individual antibodies for VPS15, VPS34, 1109 
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